Background The optimal chemotherapeutic regimen for use beyond the second line for
patients with metastatic colorectal cancer (mCRC) remains unclear. Materials and methods …

New therapeutic options for refractory metastatic colorectal cancer (mCRC) include
trifluridine/tipiracil (TAS-102) and regorafenib. However, the optimal chemotherapeutic …

Colorectal cancer (CRC) is a public health problem: it is the third most common cancer in
men (746,000 new cases/year) and the second in women (614,000 new cases/year) …

Introduction: Intravenous administration of fluoropyrimidine-based chemotherapy has been
the cornerstone of treatment in metastatic colorectal cancer (mCRC) for decades. The …

Regorafenib and trifluridine/tipiracil (TAS-102) are novel antitumor agents for patients with
refractory metastatic colorectal cancer. However, it is unclear which patients may derive a …

Background Treatment sequencing for patients with refractory metastatic colorectal cancer
(mCRC) has been highly debated. The thymidine-based nucleoside trifluridine/tipiracil (TAS …

Importance In metastatic colorectal cancer, induction combination chemotherapy with a
targeted agent is considered the mainstay of treatment. Multiple randomized clinical trials …

Background The treatment of patients with metastatic colorectal cancer (mCRC) has evolved
during the past 2 decades, and patient survival has increased. Consequently, patients are …

The response to first-line therapy is a primary determinant of outcome in patients with
metastatic colorectal cancer (mCRC), for three main reasons: effective upfront therapy …

In this review article we discuss the evolution of second-line treatment options for patients
with metastatic colorectal cancer (mCRC). The benefits of second-line chemotherapy have …